Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: GlobeNewswire
Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s diseaseTopline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025Cash, cash equivalents and marketable securities balance of $192.6M as of September 30, 2025, expected to fund planned operations into at least H2 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported third quarter financial results and highlighted recent pipeline and business progress. “I am proud of the Ventyx team for achieving two
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- Ventyx Provides Clinical and Corporate UpdatesGlobeNewswire
- Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Ventyx Biosciences: Why Caution Should Remain [Seeking Alpha]Seeking Alpha
- Ventyx Biosciences (NASDAQ:VTYX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $14.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
VTYX
Earnings
- 11/6/25 - Beat
VTYX
Sec Filings
- 11/26/25 - Form SCHEDULE
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- VTYX's page on the SEC website